01652.HK
Fusen Pharmaceutical Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 0.74
−5.73%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 517.3M | 273.4M | 326.0M | 565.6M | 491.8M |
| Cost of Revenue | 301.5M | 163.6M | 163.4M | 266.1M | 266.7M |
| Gross Profit | 215.7M | 109.8M | 162.6M | 299.5M | 225.0M |
| Operating Expenses | |||||
| R&D Expense | 68.0M | 13.3M | 106.3M | 81.0M | 15.4M |
| SG&A Expense | 178.0M | 82.8M | 141.3M | 214.4M | 188.6M |
| General & Admin Expense | 57.6M | 33.5M | 60.3M | 74.9M | 69.9M |
| Selling & Marketing Expense | 78.1M | 49.3M | 81.0M | 139.5M | 118.7M |
| Other Expenses | (2.1M) | 15.4M | (17.4M) | (15.9M) | (2.2M) |
| Total Operating Expenses | 243.9M | 111.5M | 230.1M | 279.5M | 186.4M |
| Cost and Expenses | 545.5M | 275.1M | 393.5M | 545.6M | 453.1M |
| Operating Income (EBIT) | (28.2M) | (1.7M) | (67.5M) | 20.0M | 15.7M |
| Non-Operating | |||||
| Interest Income | 255.3K | 21.0K | — | 424.0K | 2.0M |
| Interest Expense | 38.3M | 20.4M | 18.8M | 12.6M | 12.4M |
| Net Interest Income | (38.1M) | (20.3M) | (18.8M) | (12.2M) | (10.4M) |
| Other Non-Op Income/Expense | (138.1M) | (5.9M) | (122.9M) | (49.5M) | (74.8M) |
| Non-Operating Income (excl Interest) | 7.1M | — | (335.0K) | 36.9M | 62.4M |
| EBT (Pre-Tax Income) | (166.3M) | (7.6M) | (190.4M) | (29.4M) | (31.0M) |
| Income Tax Expense | 11.0M | 4.2M | (1.6M) | 6.8M | 3.7M |
| Bottom Line | |||||
| Net Income | (177.3M) | (11.8M) | (188.8M) | (36.3M) | (34.7M) |
| Earnings from Cont. Ops | (177.3M) | (11.8M) | (188.8M) | (36.3M) | (34.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (177.3M) | (11.8M) | (188.8M) | (36.3M) | (34.6M) |
| Per Share | |||||
| Basic EPS | (HK$0.23) | (HK$0.02) | (HK$0.26) | (HK$0.05) | (HK$0.05) |
| Diluted EPS | (HK$0.23) | (HK$0.02) | (HK$0.26) | (HK$0.05) | (HK$0.05) |
| Revenue Per Share | HK$0.70 | HK$0.37 | HK$0.44 | HK$0.78 | HK$0.65 |
| Shares | |||||
| Basic Shares Outstanding | 739.3M | 739.3M | 740.0M | 725.5M | 756.1M |
| Diluted Shares Outstanding | 739.3M | 739.3M | 740.0M | 752.1M | 756.1M |
| Profitability Metrics | |||||
| EBITDA | 12.0M | 11.5M | (39.1M) | 18.9M | 49.9M |
| D&A | 47.3M | 37.4M | 28.1M | 35.8M | 34.2M |
| EBIT | (35.3M) | (25.9M) | (67.2M) | (16.9M) | (18.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026